Why is BioInvent International AB ?
1
Poor long term growth as Operating profit has grown by an annual rate -181.56% of over the last 5 years
2
Negative results in Mar 26
- NET SALES(Q) At SEK 13.42 MM has Fallen at -76.29%
- PRE-TAX PROFIT(Q) At SEK -119.15 MM has Fallen at -43.36%
- NET PROFIT(Q) At SEK -119.22 MM has Fallen at -43.27%
3
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of -33.79%, its profits have risen by 20.9%
4
Below par performance in long term as well as near term
- Along with generating -33.79% returns in the last 1 year, the stock has also underperformed OMX Stockholm 30 in the last 3 years, 1 year and 3 months
How much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is BioInvent International AB for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
BioInvent International AB
-33.79%
-0.58
54.67%
OMX Stockholm 30
30.13%
1.89
15.95%
Quality key factors
Factor
Value
Sales Growth (5y)
27.03%
EBIT Growth (5y)
-181.56%
EBIT to Interest (avg)
-263.48
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.95
Sales to Capital Employed (avg)
0.19
Tax Ratio
0.03%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.91%
ROCE (avg)
0
ROE (avg)
0
Valuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.14
EV to EBIT
-2.25
EV to EBITDA
-2.39
EV to Capital Employed
473.27
EV to Sales
3.20
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-21019.35%
ROE (Latest)
-47.43%
Technical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
No Trend
Mildly Bullish
Technical Movement
7What is working for the Company
OPERATING CASH FLOW(Y)
Highest at SEK -260.56 MM
NET PROFIT(HY)
Higher at SEK -245.03 MM
DEBT-EQUITY RATIO
(HY)
Lowest at -102.53 %
RAW MATERIAL COST(Y)
Fallen by 0% (YoY
-20What is not working for the Company
NET SALES(Q)
At SEK 13.42 MM has Fallen at -76.29%
PRE-TAX PROFIT(Q)
At SEK -119.15 MM has Fallen at -43.36%
NET PROFIT(Q)
At SEK -119.22 MM has Fallen at -43.27%
ROCE(HY)
Lowest at -55.5%
CASH AND EQV(HY)
Lowest at SEK 1,049.22 MM
Here's what is working for BioInvent International AB
Debt-Equity Ratio
Lowest at -102.53 % and Grown
In each half year in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Operating Cash Flow
Highest at SEK -260.56 MM
in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (SEK MM)
Raw Material Cost
Fallen by 0% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for BioInvent International AB
Net Sales
At SEK 13.42 MM has Fallen at -76.29%
over average net sales of the previous four periods of SEK 56.62 MMMOJO Watch
Near term sales trend is extremely negative
Net Sales (SEK MM)
Pre-Tax Profit
At SEK -119.15 MM has Fallen at -43.36%
over average net sales of the previous four periods of SEK -83.12 MMMOJO Watch
Near term Pre-Tax Profit trend is very negative
Pre-Tax Profit (SEK MM)
Net Profit
At SEK -119.22 MM has Fallen at -43.27%
over average net sales of the previous four periods of SEK -83.21 MMMOJO Watch
Near term Net Profit trend is very negative
Net Profit (SEK MM)
Cash and Eqv
Lowest at SEK 1,049.22 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents






